{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:36:29Z","timestamp":1761129389552},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T00:00:00Z","timestamp":1476835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T00:00:00Z","timestamp":1476835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00228-016-2146-6","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T22:43:55Z","timestamp":1476830635000},"page":"1-14","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24"],"prefix":"10.1007","volume":"73","author":[{"given":"Helena H.","family":"Borba","sequence":"first","affiliation":[]},{"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[]},{"given":"Laiza M.","family":"Steimbach","sequence":"additional","affiliation":[]},{"given":"Cassio M.","family":"Perlin","sequence":"additional","affiliation":[]},{"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[]},{"given":"Maria L. A.","family":"Pedroso","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,10,19]]},"reference":[{"issue":"20","key":"2146_CR1","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang TJ, Ghany MG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368(20):1907\u20131917. doi:10.1056\/NEJMra1213651","journal-title":"N Engl J Med"},{"issue":"12","key":"2146_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrgastro.2013.163","volume":"10","author":"PM Trembling","year":"2013","unstructured":"Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM (2013) Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 10(12):713\u2013728. doi:10.1038\/nrgastro.2013.163nrgastro.2013.163","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2146_CR3","first-page":"189","volume":"26","author":"A Fernandez-Yunquera","year":"2013","unstructured":"Fernandez-Yunquera A, Rincon D, Salcedo M, Banares R (2013) Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection. Rev Esp Quimioter 26(3):189\u2013192","journal-title":"Rev Esp Quimioter"},{"issue":"4","key":"2146_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49(4):1335\u20131374. doi:10.1002\/hep.22759","journal-title":"Hepatology"},{"issue":"3","key":"2146_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3949\/ccjm.79a.11082","volume":"79","author":"N Alkhouri","year":"2012","unstructured":"Alkhouri N, Zein NN (2012) Protease inhibitors: silver bullets for chronic hepatitis C infection? Cleve Clin J Med 79(3):213\u2013222. doi:10.3949\/ccjm.79a.1108279\/3\/213","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"2146_CR6","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","volume":"56","author":"C Moreno","year":"2012","unstructured":"Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G (2012) Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 56(6):1247\u20131253. doi:10.1016\/j.jhep.2011.12.033S0168-8278(12)00116-X","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"2146_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/liv.12424","volume":"34","author":"T Asselah","year":"2014","unstructured":"Asselah T, Marcellin P (2014) Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 34(Suppl 1):60\u201368. doi:10.1111\/liv.12424","journal-title":"Liver Int"},{"key":"2146_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2147\/TCRM.S50170","volume":"10","author":"T Kanda","year":"2014","unstructured":"Kanda T, Nakamoto S, Wu S, Yokosuka O (2014) New treatments for genotype 1 chronic hepatitis C - focus on simeprevir. Ther Clin Risk Manag 10:387\u2013394. doi:10.2147\/TCRM.S50170tcrm-10-387","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"2146_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/gutjnl-2013-305771","volume":"63","author":"Z Marino","year":"2014","unstructured":"Marino Z, van Bommel F, Forns X, Berg T (2014) New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut 63(2):207\u2013215. doi:10.1136\/gutjnl-2013-305771gutjnl-2013-305771","journal-title":"Gut"},{"issue":"8","key":"2146_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11908-014-0413-1","volume":"16","author":"C Moore","year":"2014","unstructured":"Moore C, Levitsky J (2014) The current state and future prospects of chronic hepatitis C virus infection treatment. Curr Infect Dis Rep 16(8):413. doi:10.1007\/s11908-014-0413-1","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"2146_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/jvh.12464","volume":"23","author":"M Lagging","year":"2016","unstructured":"Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N (2016) Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat 23(2):80\u201388","journal-title":"J Viral Hepat"},{"issue":"6","key":"2146_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","volume":"64","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourli\u00e8re M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Br\u00e4u N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S (2015) Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 64(6):948\u2013956","journal-title":"Gut"},{"issue":"16","key":"2146_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Bisceglie AMD, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370(16):1483\u20131493","journal-title":"N Engl J Med"},{"issue":"9","key":"2146_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-015-0412-z","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED (2015) Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection. Drugs 75(9):1027\u20131038","journal-title":"Drugs"},{"issue":"5","key":"2146_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-016-0558-3","volume":"76","author":"GM Keating","year":"2016","unstructured":"Keating GM (2016) Elbasvir\/grazoprevir: first global approval. Drugs 76(5):617\u2013624. doi:10.1007\/s40265-016-0558-310.1007\/s40265-016-0558-3","journal-title":"Drugs"},{"issue":"6","key":"2146_CR16","doi-asserted-by":"publisher","first-page":"e18640","DOI":"10.5812\/hepatmon.15(6)2015.18640","volume":"15","author":"A Federico","year":"2015","unstructured":"Federico A, Masarone M, Romano M, Dallio M, Rosato V, Persico M (2015) Rapid virological response represents the highest prediction factor of response to antiviral treatment in HCV-related chronic hepatitis: a multicenter retrospective study. Hepat Mon 15(6):e18640. doi:10.5812\/hepatmon.15(6)2015.18640","journal-title":"Hepat Mon"},{"issue":"1","key":"2146_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"2146_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. doi:10.1136\/bmj.d5928bmj.d5928","journal-title":"BMJ"},{"issue":"5","key":"2146_CR19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","volume":"11","author":"JP Jansen","year":"2008","unstructured":"Jansen JP, Crawford B, Bergman G, Stam W (2008) Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 11(5):956\u2013964. doi:10.1111\/j.1524-4733.2008.00347.xVHE347","journal-title":"Value Health"},{"issue":"4","key":"2146_CR20","doi-asserted-by":"publisher","first-page":"e0121715","DOI":"10.1371\/journal.pone.0121715","volume":"10","author":"JD Chambers","year":"2015","unstructured":"Chambers JD, Naci H, Wouters OJ, Pyo J, Gunjal S, Kennedy IR, Hoey MG, Winn A, Neumann PJ (2015) An assessment of the methodological quality of published network meta-analyses: a systematic review. PLoS One 10(4):e0121715. doi:10.1371\/journal.pone.0121715PONE-D-14-31747","journal-title":"PLoS One"},{"key":"2146_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","volume":"55","author":"G Valkenhoef","year":"2013","unstructured":"Valkenhoef G, Tervonen T, Zwinkels T, Brock B, Hillege H (2013) ADDIS: a decision support system for evidence-based medicine. Decis Support Syst 55:459\u2013475","journal-title":"Decis Support Syst"},{"issue":"7\u20138","key":"2146_CR22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29(7\u20138):932\u2013944. doi:10.1002\/sim.3767","journal-title":"Stat Med"},{"issue":"1","key":"2146_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N (2012) Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 56(1):78\u201384. doi:10.1016\/j.jhep.2011.07.016S0168-8278(11)00610-6","journal-title":"J Hepatol"},{"issue":"1","key":"2146_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/hep.26624","volume":"59","author":"BL Pearlman","year":"2014","unstructured":"Pearlman BL, Ehleben C (2014) Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon\/ribavirin obviates a protease inhibitor. Hepatology 59(1):71\u201377. doi:10.1002\/hep.26624","journal-title":"Hepatology"},{"issue":"7","key":"2146_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M (2014) Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146(7):1669\u20131679.e1663. doi:10.1053\/j.gastro.2014.02.051S0016-5085(14)00293-5","journal-title":"Gastroenterology"},{"issue":"2","key":"2146_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S (2014) Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 61(2):219\u2013227. doi:10.1016\/j.jhep.2014.04.004S0168-8278(14)00221-9","journal-title":"J Hepatol"},{"issue":"25","key":"2146_CR27","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405\u20132416. doi:10.1056\/NEJMoa1012912","journal-title":"N Engl J Med"},{"issue":"9941","key":"2146_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384(9941):403\u2013413. doi:10.1016\/S0140-6736(14)60494-3S0140-6736(14)60494-3","journal-title":"Lancet"},{"issue":"9742","key":"2146_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376(9742):705\u2013716. doi:10.1016\/S0140-6736(10)60934-8S0140-6736(10)60934-8","journal-title":"Lancet"},{"issue":"9941","key":"2146_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384(9941):414\u2013426. doi:10.1016\/S0140-6736(14)60538-9S0140-6736(14)60538-9","journal-title":"Lancet"},{"issue":"2","key":"2146_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1053\/j.gastro.2014.04.006","volume":"147","author":"MP Manns","year":"2014","unstructured":"Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N (2014) The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 147(2):366\u2013376.e366. doi:10.1053\/j.gastro.2014.04.006","journal-title":"Gastroenterology"},{"issue":"18","key":"2146_CR32","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360(18):1827\u20131838. doi:10.1056\/NEJMoa0806104360\/18\/1827","journal-title":"N Engl J Med"},{"issue":"9","key":"2146_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","volume":"12","author":"S Pol","year":"2012","unstructured":"Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hezode C, Lim JK, Bronowicki JP, Abrams GA, Brau N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 12(9):671\u2013677. doi:10.1016\/s14733099(12)70138-x","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2146_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","volume":"15","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W (2015) Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 15(1):27\u201335. doi:10.1016\/s1473-3099(14)71002-3","journal-title":"Lancet Infect Dis"},{"key":"2146_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13288","author":"L Wei","year":"2016","unstructured":"Wei L, Han T, Yang D, Heo J, Shang J, Cheng J, Chen X, Xie Q, Kim JH, Kalmeijer R, Ouwerkerk-Mahadevan S, Hoeben E, Lenz O, Verbinnen T, Sinha R, Li M, Scott J, Peeters M, Witek J (2016) Simeprevir plus peginterferon\/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea. J Gastroenterol Hepatol. doi:10.1111\/jgh.13288","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2146_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","volume":"146","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M (2014) Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146(2):430\u2013441.e436. doi:10.1053\/j.gastro.2013.10.058S0016-5085(13)01576-X","journal-title":"Gastroenterology"},{"issue":"13","key":"2146_CR37","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207\u20131217. doi:10.1056\/NEJMoa1009482","journal-title":"N Engl J Med"},{"issue":"1","key":"2146_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cgh.2012.10.006","volume":"11","author":"SL Flamm","year":"2013","unstructured":"Flamm SL, Lawitz E, Jacobson I, Bourliere M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F (2013) Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 11(1):81\u201387.e84; quiz e85. doi:10.1016\/j.cgh.2012.10.006S1542-3565(12)01160-3","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"2146_CR39","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195\u20131206. doi:10.1056\/NEJMoa1010494","journal-title":"N Engl J Med"},{"issue":"4","key":"2146_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jrsm.1085","volume":"4","author":"S Donegan","year":"2013","unstructured":"Donegan S, Williamson P, D\u2019Alessandro U, Tudur Smith C (2013) Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods 4(4):291\u2013323. doi:10.1002\/jrsm.1085","journal-title":"Res Synth Methods"},{"issue":"11","key":"2146_CR41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/M15-0930","volume":"162","author":"JE Cornell","year":"2015","unstructured":"Cornell JE (2015) The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses. Ann Intern Med 162(11):797\u2013798. doi:10.7326\/M15-09302299863","journal-title":"Ann Intern Med"},{"key":"2146_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.17235\/reed.2015.3840\/2015","volume":"107","author":"X Cui","year":"2015","unstructured":"Cui X, Kong Y, Jia J (2015) Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials. Rev Esp Enferm Dig 107:591\u20137. doi:10.17235\/reed.2015.3840\/2015","journal-title":"Rev Esp Enferm Dig"},{"key":"2146_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clinre.2015.06.021","volume":"40","author":"Y Qu","year":"2015","unstructured":"Qu Y, Li T, Wang L, Liu F, Ye Q (2015) Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. Clin Res Hepatol Gastroenterol 40:203\u201312. doi:10.1016\/j.clinre.2015.06.021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"2146_CR44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/qjmed\/hcu202","volume":"108","author":"E Druyts","year":"2015","unstructured":"Druyts E, Lorenzi M, Toor K, Thorlund K, Mills EJ (2015) Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. QJM 108(4):299\u2013306. doi:10.1093\/qjmed\/hcu202hcu202","journal-title":"QJM"},{"key":"2146_CR45","doi-asserted-by":"publisher","unstructured":"Taieb V, Pacou M, Ho S, Pettre S, Van Sanden S, Pisini M, Ustianowski A, Mehnert A (2015) A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-alpha and ribavirin in patients infected with genotype 1 hepatitis C virus. J Med Econ:1\u201310. doi:10.3111\/13696998.2015.1046880","DOI":"10.3111\/13696998.2015.1046880"},{"issue":"9","key":"2146_CR46","doi-asserted-by":"publisher","first-page":"e3004","DOI":"10.1097\/MD.0000000000003004","volume":"95","author":"GQ Zhu","year":"2016","unstructured":"Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT, Shi KQ, Zheng MH (2016) Systematic review and network meta-analysis of randomized controlled trials: comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C genotype 1. Medicine (Baltimore) 95(9):e3004. doi:10.1097\/MD.000000000000300400005792-201603010-00078","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"2146_CR47","doi-asserted-by":"publisher","first-page":"e0145953","DOI":"10.1371\/journal.pone.0145953","volume":"10","author":"T Suwanthawornkul","year":"2015","unstructured":"Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y (2015) Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C genotype 1: a systematic review and network meta-analysis. PLoS One 10(12):e0145953. doi:10.1371\/journal.pone.0145953PONE-D-15-40476","journal-title":"PLoS One"},{"key":"2146_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-230X-13-148","volume":"13","author":"AD Goralczyk","year":"2013","unstructured":"Goralczyk AD, Cameron S, Amanzada A (2013) Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naive and -experienced patients. BMC Gastroenterol 13:148. doi:10.1186\/1471-230X-13-1481471-230X-13-148","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"2146_CR49","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1185\/03007995.2012.734798","volume":"28","author":"S Cure","year":"2012","unstructured":"Cure S, Diels J, Gavart S, Bianic F, Jones E (2012) Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin 28(11):1841\u20131856. doi:10.1185\/03007995.2012.734798","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2146_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/qjmed\/hcs214","volume":"106","author":"C Cooper","year":"2013","unstructured":"Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ (2013) Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 106(2):153\u2013163. doi:10.1093\/qjmed\/hcs214hcs214","journal-title":"QJM"},{"issue":"2","key":"2146_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/cid\/cis880","volume":"56","author":"J Kieran","year":"2013","unstructured":"Kieran J, Schmitz S, O\u2019Leary A, Walsh C, Bergin C, Norris S, Barry M (2013) The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 56(2):228\u2013235. doi:10.1093\/cid\/cis880cis880","journal-title":"Clin Infect Dis"},{"key":"2146_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12467","author":"JM Quigley","year":"2015","unstructured":"Quigley JM, Bryden PA, Scott DA, Kuwabara H, Cerri K (2015) Relative efficacy and safety of simeprevir and telaprevir in treatment-naive hepatitis C-infected patients in a Japanese population: a Bayesian network meta-analysis. Hepatol Res. doi:10.1111\/hepr.12467","journal-title":"Hepatol Res"},{"issue":"4","key":"2146_CR53","doi-asserted-by":"publisher","first-page":"e94542","DOI":"10.1371\/journal.pone.0094542","volume":"9","author":"N Coppola","year":"2014","unstructured":"Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF (2014) Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One 9(4):e94542. doi:10.1371\/journal.pone.0094542PONE-D-13-38118","journal-title":"PLoS One"},{"issue":"12","key":"2146_CR54","doi-asserted-by":"publisher","first-page":"e52158","DOI":"10.1371\/journal.pone.0052158","volume":"7","author":"Y Kong","year":"2012","unstructured":"Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X (2012) Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS One 7(12):e52158. doi:10.1371\/journal.pone.0052158PONE-D-11-26035","journal-title":"PLoS One"},{"issue":"6","key":"2146_CR55","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2169\/internalmedicine.52.8156","volume":"52","author":"D Yang","year":"2013","unstructured":"Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z (2013) The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Intern Med 52(6):653\u2013660","journal-title":"Intern Med"},{"issue":"3","key":"2146_CR56","first-page":"263","volume":"37","author":"S Lanini","year":"2014","unstructured":"Lanini S, Mammone A, Puro V, Girardi E, Bruzzi P, Ippolito G (2014) Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach. New Microbiol 37(3):263\u2013276","journal-title":"New Microbiol"},{"issue":"1","key":"2146_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jcpt.12106","volume":"39","author":"C Park","year":"2014","unstructured":"Park C, Jiang S, Lawson KA (2014) Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther 39(1):14\u201324. doi:10.1111\/jcpt.12106","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2146_CR58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1665-2681(19)30800-2","volume":"14","author":"C Manzano-Robleda Mdel","year":"2015","unstructured":"Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutierrez T, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC (2015) Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann Hepatol 14(1):46\u201357","journal-title":"Ann Hepatol"},{"issue":"114","key":"2146_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5754\/hge11312","volume":"59","author":"SS Dang","year":"2012","unstructured":"Dang SS, Wang WJ, Wang XF, Li YP, Li M, Jia XL, Wang Y, Liu E, Zhao S (2012) Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis. Hepato-Gastroenterology 59(114):461\u2013468. doi:10.5754\/hge11312","journal-title":"Hepato-Gastroenterology"},{"issue":"2","key":"2146_CR60","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clinthera.2012.12.017","volume":"35","author":"M Sitole","year":"2013","unstructured":"Sitole M, Silva M, Spooner L, Comee MK, Malloy M (2013) Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther 35(2):190\u2013197. doi:10.1016\/j.clinthera.2012.12.017S0149-2918(12)00734-5","journal-title":"Clin Ther"},{"issue":"12","key":"2146_CR61","first-page":"963","volume":"67","author":"L Gu","year":"2012","unstructured":"Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N (2012) Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis. Pharmazie 67(12):963\u2013972","journal-title":"Pharmazie"},{"issue":"10","key":"2146_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/BF03261920","volume":"32","author":"H Qin","year":"2012","unstructured":"Qin H, Li H, Zhou X, Feng F, Shen Y, Tan H, Ye F, Xie Y (2012) Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clin Drug Investig 32(10):665\u2013672. doi:10.2165\/11633240-000000000-00000","journal-title":"Clin Drug Investig"},{"issue":"2","key":"2146_CR63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jhep.2014.03.022","volume":"61","author":"JM Vierling","year":"2014","unstructured":"Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S (2014) Safety and efficacy of boceprevir\/peginterferon\/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 61(2):200\u2013209. doi:10.1016\/j.jhep.2014.03.022S0168-8278(14)00203-7","journal-title":"J Hepatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2146-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-016-2146-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2146-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:47:07Z","timestamp":1659109627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-016-2146-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,19]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["2146"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2146-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,19]]},"assertion":[{"value":"1 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}